Who We Are

Medical device and biopharmaceutical companies trust JD LYMON, based in Minnesota’s Medical Alley, to develop creative, street smart solutions to overcome barriers to market access, de-risk potential problems before they arise, and provide the guidance to smooth out the path to market success.

Founded by three highly respected healthcare strategists with more than 70 years of combined experience, JD LYMON creates strategic, integrated, multidisciplinary pathways that help medical device and biopharmaceutical companies understand their unique value proposition and optimize their market potential.

At every stage of development - from an idea on a napkin to your company’s next acquisition - JD LYMON serves as a collaborative partner dedicated to accelerating market access for groundbreaking medical and biopharmaceutical technology.

THE NEXT BIG THING IN HEALTHCARE:
YOUR COMPANY.

×

Jolayne Devers

Principal - MBA, CPC, COC, CPC-P

For JD LYMON clients, Jolayne Devers develops and executes successful strategies in the areas of coding, coverage, and payment for the commercialization of new products into the marketplace. Her customized reimbursement solutions effectively integrate with clinical, regulatory, sales and marketing. Jolayne currently provides CPT, RUC and strategic consulting to the American Society of General Surgery to help guide them on the political and economic changes that affect general surgeons and the quality care they provide for their patients.

×

Chris Lyle

Principal - MS

Chris Lyle provides analytical consulting services, including statistical trial design and analysis, literature synthesis, and health economic modeling for JD LYMON. He has successfully worked with the FDA on numerous occasions to obtain agreement on IDE study designs. He works closely with our clients to ensure their research efforts support both product approval and demonstrate value to payers.

×

Carla Monacelli

Chair & Strategic Advisor

Carla Monacelli develops and implements strategic reimbursement plans for both biotechnology and medical device companies. She has been involved with the launch or reimbursement strategies for hundreds of technologies, including multiple companies that have had successful exits. Her strength lies in working with clients to integrate healthcare policy and reimbursement solutions into an organization’s overall business plan, examining the trade-offs and timing of various strategies, ultimately resulting in removing reimbursement as a barrier to market adoption.